U.S. Life Sciences Stock News

Pebblebrook Hotel Trust (NYSE:PEB) recently completed a $450 million senior unsecured term loan. The company used part of the proceeds to repay certain mortgages and address near term debt maturities. Management also restored full capacity on its revolving credit facility, increasing available liquidity. Pebblebrook Hotel Trust, trading at $12.24, has had mixed share performance, with a 6.0% return year to date and a 4.6% return over the past year, but weaker 3 year and 5 year returns of...

If you are wondering whether Perfect's current share price reflects its true worth, this breakdown will help you connect the recent market action to what the numbers actually say about value. Perfect's share price closed at US$1.38, with returns of a 5.5% decline over 7 days, a 17.4% decline over 30 days, a 20.2% decline year to date, a 27.7% decline over 1 year and 81.9% and 86.1% declines over 3 and 5 years. This performance sits against a backdrop of ongoing market attention on software...

Matador Resources (MTDR) has wrapped up FY 2025 with fourth quarter revenue of US$848 million and basic EPS of US$1.55, alongside net income excluding extra items of US$192.5 million. This gives investors a clear read on its latest run rate. Over the past year, total revenue on a trailing twelve month basis has moved from US$3.24 billion in Q4 2024 to US$3.70 billion in Q4 2025, while trailing basic EPS shifted from US$7.16 to US$6.10, framing the current quarter against a fuller year of...

MGP Ingredients (MGPI) FY 2025 earnings snapshot MGP Ingredients (MGPI) has just wrapped up FY 2025 with fourth quarter revenue of US$138.3 million, Basic EPS of US$6.22 loss, and a net income loss excluding extra items of US$133.0 million. Over the past few quarters, the company has seen revenue move from US$161.5 million in Q3 FY 2024 to US$130.9 million in Q3 FY 2025 and EPS shift from US$1.07 in Q3 FY 2024 to US$0.71 in Q3 FY 2025, while trailing twelve month EPS moved from US$1.56 in Q4...

Recent performance snapshot Kinetik Holdings (KNTK) has been drawing attention after a recent mix of short term and longer term share moves, including a 1.5% decline in the latest session and a 2.3% pullback over the past week. Over the past month the stock shows a 9.0% gain, while the past 3 months reflect a 28.5% return, alongside a 19.3% gain year to date and a 19.7% decline over the past year. See our latest analysis for Kinetik Holdings. The recent 9.1% 1 month share price return and...

ONEOK (NYSE:OKE) reported double digit net income and adjusted EBITDA growth for 2025. The company exceeded synergy targets from recent acquisitions, including Magellan, and retired a significant amount of long term debt. ONEOK raised its quarterly dividend by 4% and continued integrating acquired assets through 2025. Management outlined plans for 2026 that include expansion into fee based earnings and energy solutions for data centers. ONEOK is a large midstream operator focused on natural...

If you are wondering whether Navios Maritime Partners is still attractively priced or already reflecting a lot of optimism, this article is here to break that question down into plain terms. The stock last closed at US$68.11, with returns of 5.5% over 7 days, 17.2% over 30 days, 32.5% year to date and 60.3% over the past year. That performance is likely to catch the eye of investors thinking about growth potential and changing risk perceptions. Recent news coverage around Navios Maritime...

Matson (MATX) has wrapped up FY 2025 with fourth quarter revenue of US$851.9 million and basic EPS of US$4.65, alongside full year trailing twelve month revenue of about US$3.3 billion and EPS of US$13.99. Over the past six reported quarters, revenue has moved between US$782 million and US$962 million, while quarterly EPS has ranged from US$2.20 to US$5.98, giving investors a clear view of how trading conditions have flowed through to the bottom line. With a trailing net margin of 13.3% and...

Circle Internet Group (CRCL) just posted its FY 2025 Q4 numbers, with revenue of US$770.2 million and basic EPS of US$0.56, against a trailing twelve month revenue base of US$2.7 billion and basic EPS of US$0.44 loss. The company has seen quarterly revenue move from US$435.4 million in Q4 2024 to US$770.2 million in Q4 2025. Basic EPS shifted from US$0.08 in Q4 2024 through a volatile FY 2025 that included a US$4.48 loss in Q2 before settling at US$0.56 in Q4. This sets the stage for...

Ameriprise Financial (AMP) is in focus after reporting record fourth quarter 2025 earnings and client assets. The stock moved following results that reflected favorable markets, strong inflows, and increased analyst optimism. See our latest analysis for Ameriprise Financial. At a share price of $478.25, Ameriprise’s recent 1 day share price return of 2.58% clusters around the Q4 earnings release. However, the 30 day share price return of 4.45% and 1 year total shareholder return of a 7.77%...

BioMarin Pharmaceutical has entered into a definitive agreement to acquire Amicus Therapeutics. The deal marks a major change for Amicus Therapeutics and its commercial portfolio. The transaction is viewed as a material event for shareholders and the wider biotechnology sector. For investors watching Amicus Therapeutics, NasdaqGM:FOLD, the new acquisition agreement with BioMarin comes at a time when the stock is trading at $14.34. Over the past year, the share price return of 58.8% and...

Hippo Holdings FY 2025 Earnings: Profitability Backdrop Comes Into Focus Hippo Holdings (HIPO) has wrapped up FY 2025 with fourth quarter revenue of US$119.4 million, basic EPS of US$0.24 and net income of US$6 million, against a backdrop where trailing twelve month EPS sits at US$2.28 on revenue of US$467.6 million and net income of US$57.7 million. Over recent periods, the company has seen revenue move from US$101.9 million in Q4 2024 to US$119.4 million in Q4 2025, while quarterly basic...

Camping World Holdings FY 2025 Earnings Snapshot Camping World Holdings (CWH) has wrapped up FY 2025 with fourth quarter revenue of US$1.2 billion and a basic EPS loss of US$1.07, while trailing twelve month revenue came in at US$6.4 billion with a full year basic EPS loss of US$1.43. Over recent quarters the company has seen quarterly revenue range from US$1.4 billion to US$2.0 billion, with basic EPS moving from a profit of US$0.48 in Q2 2025 to losses in Q1, Q3 and Q4. This sets up a mixed...

Stanley Black & Decker (SWK) closed out FY 2025 with Q4 revenue of US$3.7b and basic EPS of US$1.04 on net income of US$158.2m, setting the tone for how investors will read the full year. Over recent quarters, revenue has moved in a tight band between US$3.7b and US$3.9b, while quarterly EPS has ranged from US$0.34 to US$1.04, with trailing twelve month EPS at US$2.66 on revenue of US$15.1b. As a result, the focus now is on how efficiently those sales are turning into profit and what that...

If you are wondering whether Vita Coco Company stock is still attractively priced after a strong run, this article will walk through what the current market price might be implying about its value. The share price recently closed at US$55.07, with returns of 10.0% over 7 days, 0.4% over 30 days, 3.0% year to date and 63.4% over 1 year, while the 3 year return stands at 221.9%. Recent attention on Vita Coco has focused on its position in the branded coconut water and functional beverage...

Chevron (CVX) closed out FY 2025 with fourth quarter revenue of US$45.1b and basic EPS of US$1.39, alongside trailing 12 month revenue of US$184.7b and EPS of US$6.65. Over recent quarters, revenue moved between US$44.5b and US$49.2b while quarterly EPS ranged from US$1.39 to US$2.49, giving investors a clear view of how the top line and per share earnings have tracked through the year. With net income of US$2.8b in the latest quarter and trailing 12 month profit of US$12.3b, the focus now...

If you are wondering whether Advance Auto Parts shares are now a bargain or still a value trap, this article walks through what the current price is really telling you. The stock recently closed at US$50.44, after a 9.8% decline over the last 7 days, a 6.1% gain over 30 days, a 29.7% gain year to date, a 36.9% gain over 1 year, but with 3 year and 5 year returns of 61.1% and 65.8% declines respectively. These moves sit against a backdrop of ongoing attention on the company’s turnaround...

Hovnanian Enterprises (HOV) opened its 2026 financial year with Q1 revenue of US$632 million and basic EPS of US$2.80, setting a measured tone after a volatile run of quarterly results. The company has seen quarterly revenue move from US$674 million and EPS of US$3.88 in Q1 2025 through periods of both profit and loss, including revenue of US$818 million with a loss per share of US$0.60 in Q4 2025. This puts today’s figures in the middle of a choppy trend that keeps the spotlight firmly on...

Kiniksa Pharmaceuticals International (KNSA) closed FY 2025 with Q4 revenue of US$202.1 million and basic EPS of US$0.19, alongside net income of US$14.2 million. On a trailing twelve month basis, revenue was US$677.6 million with basic EPS of US$0.80 and net income of US$59.0 million. The company’s quarterly revenue moved from US$122.5 million and a basic EPS loss of US$0.12 in Q4 2024 to US$202.1 million and basic EPS of US$0.19 in Q4 2025. Over the same period, trailing twelve month net...

CareDx (CDNA) just wrapped up FY 2025 with Q4 revenue of US$108.4 million, basic EPS of US$0.08 loss, and net income loss of US$4.1 million, while trailing twelve month figures show revenue of US$379.8 million and a net income loss of US$21.4 million. Over recent quarters, the company has seen revenue move from US$86.6 million in Q2 2025 to US$100.1 million in Q3 2025 and then to US$108.4 million in Q4 2025, with EPS shifting from a US$0.19 loss in Q1 2025 to a small profit of US$0.03 in Q3...

Primoris Services (PRIM) has wrapped up FY 2025 with Q4 revenue of US$1.9b and basic EPS of US$0.96, while trailing twelve month revenue reached about US$7.6b and EPS came in at US$5.09 as earnings grew 52% over the past year. The company has seen revenue move from US$6.4b to US$7.6b and trailing net income rise from US$180.9m to US$274.9m over the last year, presenting a picture of expanding profits and firmer margins across the construction and infrastructure work it delivers. See our full...

What Avidity Biosciences’ Recent Returns Signal for Investors Avidity Biosciences (RNA) has drawn attention after a 1 day return close to flat, modest moves over the past week and month, and a very large total return over the past year. For investors, those figures sit alongside a revenue base of US$18.755 million and a reported net loss of US$684.631 million. This highlights that the company remains firmly in a development focused phase. See our latest analysis for Avidity Biosciences. With...

Day One Biopharmaceuticals (DAWN) just reported its FY 2025 numbers, with Q4 total revenue of US$53.7 million and a net loss of US$21.3 million, setting the tone for how investors will read the year as a whole. The company has seen quarterly revenue move from US$29.2 million in Q4 2024 to US$53.7 million in Q4 2025, while Basic EPS shifted from a loss of US$0.64 per share in Q4 2024 to a loss of US$0.19 per share in Q3 2025, giving investors a clear view of how top line scale and loss levels...

Setting the scene on ACV Auctions ACV Auctions (ACVA) has drawn investor attention after a prolonged share price slump, with the stock showing negative returns over the past month, past 3 months, and year to date. At a last close of US$4.51, the wholesale digital auction platform sits against a backdrop of reported annual revenue of US$759.6 million and a net loss of US$66.1 million. This raises questions about how the business fundamentals compare with recent market sentiment. See our latest...